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Summary The anti-breast carcinoma monoclonal antibody (MAb), NCRC- 11 defines a polymorphic
epithelial mucin (PEM) which is elevated in the circulation of advanced breast carcinoma patients. Here we
describe the purification and partial characterisation of this component from patients' sera and its use in the
production of a second generation MAb, C568 (IgM). Pooled sera was fractionated by immunoaffinity and
size-exclusion chromatography and the purity of preparations assessed by sodium dodecyl sulphate poly-
acrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. Serum-derived PEM shows a similar pattern
of electrophoretic mobility to PEM isolated from primary breast tumour tissue and migrates as several bands
in 4% SDS polyacrylamide gels (Mr> 400,000). The epitope expression of PEMs isolated from either source
is also similar, with both bearing topographically distinct determinants for several anti-mucin MAbs. The
immunoreactivities of antibodies C568 and NCRC-11 were unaffected by boiling, reduction and alkylation, or
by enzyme desialylation of PEM. Periodate oxidation and proteolytic digestion have suggested that the
antigenic determinant for C568 is carbohydrate in nature whilst that of NCRC- II is peptidic. In accord with
the mucinous nature of the molecule, serum-derived PEM is susceptible to reductive P-elimination, elutes in
the void volume of a Sepharose CL-4B column and has a buoyant density of 1.45 g ml-'.
In Western countries breast carcinoma affects an estimated
one in fourteen women and is responsible for the highest
female mortality rate due to any form of malignancy (Tag-
non, 1986). Consequently, the immunological detection of a
carcinoma-associated marker which differentiates normal
from malignant cells has become increasingly important.
Since the advent of monoclonal antibody (MAb) technology,
a considerable number of antibodies have been described
which recognise breast carcinoma-associated antigens. These
antigens show marked variations in molecular weight and
tissue distribution and consequently, the antibodies defining
them vary widely in their selectivity towards malignant tissue.
Several of these antibodies define epitopes on a high
molecular weight mucin which is peculiar to the luminal
surface of glandular epithelial cells or their secretions and
hence is also associated with certain carcinomas. Originally
purified from human milk, this component has been termed
PAS-O by Shimizu and Yamauchi (1982), EMA (epithelial
membrane antigen) by Heyderman et al., (1979), MAM-6 by
Hilkens et al. (1984) and MSA (mammary serum antigen) by
Stacker et al. (1988). Karlsson et al. (1983) first reported that
the mucin exhibits a genetic polymorphism which was later
shown to exist at both the protein and DNA level (Swallow
et al., 1987; Gendler et al., 1987, respectively). Consequently,
Gendler et al., (1988) have named the mucin polymorphic
epithelial mucin, or PEM, a term which aptly describes its
properties.
NCRC-l1 is a murine MAb (IgM) originally produced
against metastatic breast carcinoma cells (Ellis et al., 1984).
This antibody reacts with a variety of normal and malignant
tissues of epithelial origin and immunocytochemical studies
have shown that in malignant tissue there exists a direct
relationship between the intensity of staining and patient
survival (Ellis et al., 1985). The antigen defined by NCRC-l
bears multiple epitopes for several anti-mucin MAbs and also
displays the same molecular weight, tissue distribution and
genetic polymorphism as PEM. Furthermore, NCRC-l1 has
recently been shown to react with the core protein of PEM
confirming the notion that the NCRC-l1 defined antigen is
indeed PEM (Price et al., 1990).
Of clinical interest, it has been reported that PEMs are
elevated in the circulation of advanced breast carcinoma
patients (Burchell et al., 1984; Hayes et al., 1985; Hilkens et
al., 1986; Price et al., 1987) and these findings have promoted
investigation into its potential as a prognostic or diagnostic
indicator. The present study describes the purification and
partial characterisation of PEM isolated from advanced
breast carcinoma patients' sera and its use in the production
of a second-generation MAb, C568.
Materials and methods
Monoclonal antibodies
NCRC-I 1 monoclonal antibody (IgM) was raised against
dissociated breast carcinoma cells as described in detail by
Ellis et al. (1984).
MAb C568 (IgM) was derived from a fusion of mouse
myeloma cells with spleen cells of a BALB/c mouse
immunised against PEM isolated from sera. Hybridoma
supernatants were screened by radioimmunoassay (RIA) for
reactivity against purified serum PEM and positive clones
selected for on this basis. Both antibodies were purified from
ascitic fluids by Sepharose-Lentil lectin affinity chromato-
graphy (Pharmacia, Uppsala, Sweden).
Other MAbs used in this study and which also identify
mucinous antigens are listed in Table I.
Solidphase RIAfor PEM detection
PEM was added to microtest plates (Falcon 3034F Terasaki
plates, Becton Dickinson, CA, USA) at 10 pl per well and
air-dried. Non-specific adsorption sites were blocked by
incubation (30 min) with phosphate buffered saline (PBS)
containing 0.1% casein (Sigma Chemical Co., Poole, Dorset).
Wells were then incubated (1-2 h, room temperature) with
10 g.l of the relevant MAb (or control) diluted in casein
buffer. Plates were washed four times with buffer and then
incubated (I h, room temperature) with 10 tl '251I-labelled
F(ab')2 fragments of rabbit anti-mouse Ig (105 c.p.m. per
well). After washing six times, the radioactivity retained in
each well was determined. Each test was performed in trip-
licate and the mean ± s.d. recorded.
In direct antibody binding assays, PEM adsorbed to plates
was detected directly by incubation with radiolabelled
NCRC-l antibody. Human IgM and IgG were detected
using radiolabelled rabbit anti-human IgM (Dako Ltd, High
Wycombe, Bucks.) and Protein A (Pharmacia), respectively.
In competitive inhibition studies, the inhibiting antibody or
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Table I MAbs to PEMs available for comparative studies
Classl
MAb subclass Immunogen Ref.
NCRC-l 1 IgM Metastatic breast cancer Ellis et al. (1984)
C568 IgM PEM from breast carcinoma patients' sera Present study
C595 IgG3 Affinity purified urinary PEM Price et al. (1989)
SM3 IgGI Deglycosylated milk mucin Burchell et al. (1987)
Cal IgM Laryngeal carcinoma (Hep 2 cells) Ashall et al. (1982)
Ca2 IgGI Cal antigen Bramwell et al. (1985)
Ca3 IgGI Desialylated Cal antigen Bramwell et al. (1985)
HMFG-1 IgGI Taylor-Papadimitriou et al. (1981)
HMFG-2 IgGI Taylor-Papadimitriou et al. (1981)
115D8 IgGI Hilkens et al. (1984)
115F5 IgGi . Hilkens et al. (1984)
115G2 IgG2 Human milk fat globule Hilkens et al. (1984)
M8 IgGI Foster et al. (1982)
M18 IgM Foster et al. (1982)
M24 IgM Foster et al. (1982)
buffer alone was admixed with equal volumes of a fixed
amount of radiolabelled NCRC-11 antibody and incubated
with PEM-coated plates for 1-2 h at room temperature. One
hundred per cent binding was taken as the radioactivity
bound using buffer alone. All reagents were labelled with 1251
(Amersham International, Bucks.) at 20 iCi tg-I using the
chloramine T method of Jensenius and Williams (1974).
SDS-polyacrylamide gel electrophoresis
SDS-PAGE was performed on an LKB Midget Gel
apparatus essentially according to the method of Laemmli
(1970) and using either 4% or 7.5% running gels with 3%
stackers. Samples were heated at 100°C for 5 min (under
reducing or non-reducing conditions) before electrophoresis.
After separation, proteins were stained with 0.25% Coomas-
sie Brilliant Blue R-250 (Sigma) or transferred on to nitrocel-
lulose membranes by Western blotting.
Immunoblotting
After electrophoresis proteins were electrophoretically trans-
ferred on to nitrocellulose membranes (Bio-Rad Laboratories
Ltd, Watford, Herts.) following the procedure of Towbin et
al. (1979). Immunostaining of serum PEM was achieved by
incubating the membrane with the following solutions at
room temperature: (a) 0.1% casein in PBS (1 h); (b) NCRC-
11 antibody (1-5pgml-') in casein buffer containing 2%
normal rabbit serum (1-2 h); (c) horseradish peroxidase-
conjugated rabbit anti-mouse Ig (Dako) (1 h). Between
incubations the membranes were washed several times with
casein buffer. Finally, bound antibodies were detected using
the peroxidase substrate of 0.4% 3-amino-9-ethyl carbazole/
0.025% H202. Detection of contaminating human immuno-
globulins (IgG and IgM) was achieved using peroxidase-
conjugated rabbit anti-human IgG and -IgM respectively
(Dako). It was possible to probe blots simultaneously with
more than one specific immunoconjugate without loss of
staining resolution (Figure 1, for example).
Isolation ofcirculating PEM
An immunoadsorbent column was prepared by coupling
20 mg NCRC- 11 antibody to 20 ml CNBr-activated Seph-
arose (Pharmacia). For each purification, 50-100 ml of
pooled advanced breast cancer patients' sera was filtered,
clarified (180,000g, 1 h) and delipidated. The sera were
diluted 10-fold in 0.1 M Tris-HCI (pH 7.6) then passaged
through the affinity column which had been equilibrated in
the same buffer. The column was then washed with buffer
and non-specifically bound material removed with a wash
containing 1 M NaCl. Bound material was eluted using 0.1 M
diethylamine (pH 11.5) and eluted fractions (2 ml) neutralised
with 1 M Tris-HCI (pH 7.6). Ten J1l aliquots of each fraction
were then assayed for PEM activity by Solid Phase RIA.
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Figure 1 SDS-PAGE Western blot analysis of isolated PEM
from breast cancer patients' sera. Steps involved in the
identification and elimination of contaminating human immuno-
globulins are shown. 7.5% gel, non-reducing conditions. The blot
was probed simultaneously, using three separate labels, for PEM,
human IgM and human IgG (details in Materials and methods).
Track 1, PEM after gel filtration ofreduced and alkylated affinity
purified material; track 2, PEM partially purified by affinity
chromatography (contaminating immunoglobulins are indicated
by arrows); track 3, human IgM standard; track 4, human IgG
standard. The molecular weight markers are myosin heavy chain
(200 kDa), phosphorylase b (92 kDa) and albumin (67 kDa).
After dialysis against PBS, pooled fractions containing PEM
were concentrated, reduced with 50 mM dithiothreitol
(30 min, room temperature) and subsequently alkylated with
75 mM iodoacetamide (1 h, room temperature, in the dark).
The sample was then chromatographed on a 113 x 1.6 cm
column of S300 gel equilibrated in PBS/0.02% NaN3 and
2 ml fractions collected and assayed for PEM activity. Frac-
tions containing PEM were pooled, concentrated and asses-
sed for purity by SDS-PAGE. Due to their high level of
glycosylation, mucins fail to stain with most standard protein
stains and, in our hands, even the PAS-silver stain failed to
give reproducible results. One criterion of purity was there-
fore the 'absence' of contaminating bands in Coomassie
stained gels.BREAST TUMOUR ASSOCIATED MUCIN 803
Density gradient ultracentrifugation
Ultracentrifugation of serum PEM was performed in a
CsCl isopycnic density gradient with a starting density of
1.43 gml-'. The gradient was formed following centrifuga-
tion in an MSE 6 x 16.5 swing-out rotor at 110,000g for
70 h at 10°C. One ml fractions were collected from the
bottom of the tube and assayed for PEM activity by RIA.
The density of each fraction was determined gravimetrically
using an analytical balance.
Chemical and enzymatic treatments
Reductive P-elimination of lyophilised PEM was performed
using 0.1 M NaOH with or without 1 M NaBH4. After incu-
bation (25 h, 37C) the solutions were neutralised with glacial
acetic acid and dialysed against PBS. Mild periodate oxida-
tion was accomplished by incubating PEM-coated plates with
0, 1, 10 and 100 mM NaIO4 in acetate buffer (50 mM,
pH 4.5) for 12 h at 4°C in the dark. Following a brief rinse
with acetate buffer, the plates were incubated with 50 mM
sodium borohydride in PBS for 30 min at room temperature.
(This treatment reduces aldehyde groups to alcohols and
prevents non-specific cross-linking of antibody to antigen.)
Plates were then washed and assayed for PEM activity by
RIA.
The following enzymatic conditions were used: Clostridium
perfringens neuraminidase (type X) 100, 10, 0 units ml ' in
acetate buffer (0.2 M, pH 5.5) containing 1 mM phenylmeth-
lysulphonyl fluoride (PMSF), 2 h, 37°C; trypsin, chymotryp-
sin, pronase E (protease, type XIV, pre-heated 60C, 1 h),
subtilisin (protease, type XXIV) and papain (containing
5 mM L-cysteine), all at 100, 10, 1, 0.1 and 0 units ml' in
0.1 M Tris-HCI (pH 8.0) containing 1 mM CaCl2 and
incubated for 1 h and 18 h at 37°C. All enzymes were
obtained from the Sigma Chemical Co.
Results
Purification ofcirculating PEM
Pooled advanced breast cancer patients' sera was applied to
an NCRC-I 1 affinity column. Fractions eluted from the col-
umn and assayed for PEM activity (Figure 2) established that
recoverable levels of circulating PEM were exhausted after
4-6 sequential passages through the column. SDS-PAGE
and Western blot analyses of affinity purified material
revealed two contaminating proteins in the preparation
(Figure 1, track 2) which were tentatively identified as IgG
and IgM. These were confirmed to be human antibodies by
running the corresponding normal standards (non-reduced
human IgG and IgM) and by immunostaining blots using
specific immunoconjugates for human Ig's (Figure 1, tracks
2-4). We have since established that these antibodies are
normal heterophile antibodies cross-reactive with the murine
NCRC-1 1 antibody bound to the column (O'Sullivan et al.,
in preparation).
In order to remove these contaminants, size exclusion
chromatography using Sepharose CL-4B was performed on
the affinity purified material. PEM elutes coincident with the
void volume indicating an apparent molecular weight in
excess of 2,000 kDa. This unexpectedly high molecular
weight elution profile is most likely the result of aggregation
of individual molecules and has also been described by other
workers (Ho et al., 1988; Miotti et al., 1985; Kalthoff et al.,
1986). Although the majority ofcontaminating antibody was
eliminated by this means, a proportion of aggregated IgM
co-eluted with the mucin. However, subsequent experiments
have shown that, by reducing the contaminating IgM into
its monomeric sub-units, it could be displaced into the in-
cluded volume of an S300 gel filtration column thus separ-
ating it from the peak of PEM activity which remains in the
void volume in S300 gel (as with CL-4B). This was achieved
by reduction and alkylation of affinity purified mucin prepar-
ations prior to size exclusion chromatography. Individual
fractions eluting from the S300 column were assayed separ-
ately, by RIAs, for the presence of PEM, human IgG and
human IgM using the appropriate radiolabels. Figure 3
confirms the virtual exclusion of all human immunoglobulin
by this method. Likewise, SDS-PAGE Western blot analysis
revealed the successful removal of previously contaminating bands (Figure 1, track 1). Reduction and alkylation of PEM
did not affect either its antigenicity or electrophoretic
mobility. Furthermore, the presence of SDS or sulphydryl
reducing agents (P-mercaptoethanol) in gel electrophoresis
had no apparent effect on the molecule. These findings are
consistent with the typically low levels of sulphur-containing
amino acids found in PEMs (Schimizu & Yamauchi, 1982,
Burchell et al., 1987; Abe & Kufe, 1989). Furthermore, no
evidence for intermolecular disulphide bonds which link
mucin multimers has been observed in this class of molecule
(Hilkens & Buijs, 1988).
In order to compare the level ofcirculating PEM found in
the sera of advanced breast cancer patients with that found
in healthy individuals, a similar fractionation ofage-matched
normal human sera was undertaken. Fractions eluted from
the affinity column also revealed the presence of circulating PEM, albeit in relatively trace amounts (Figure 2).
Epitope expression ofPEMs
A number of MAbs (see Table I) raised against various
immunogens and known to be reactive with PEMs isolated
from breast carcinoma cells were tested, by RIA, for their
reactivity against PEMs isolated from both breast carcinoma
cells and patients' sera. Figure 4 demonstates that the overall
profile of antibody reactivity is similar for antigen isolated
from either source. Clearly, the antigenic determinant for
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Figure 2 Immunoadsorbent purification of PEM from pooled
breast carcinoma patients' sera (0) compared to a similar frac-
tionation of pooled normal sera (0). Elution was achieved using
0.1 M diethylamine (pH 11.5) and individual fractions were
assayed for PEM activity by RIA.
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Figure 3 Removal of human immunoglobulin from reduced and
alkylated affinity purified PEM by size exclusion chromato-
graphy. Fractions (1.6 ml) eluting from an S300 gel filtration
column were assayed, by RIAs, for PEM, human IgG and
human IgM using '25I-labelled NCRC-I I antibody (0), 251-
labelled protein A (A) and '251-labelled anti-human IgM (0)
respectively. The exclusion volume of the column (A) and elution
points of ferritin (b, 440 kDa), IgG (C, 155 kDa) and albumin
(D, 67 kDa) are indicated by arrows.
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Figure 4 Comparative epitope expression of PEM using the
anti-PEM MAbs listed in Table 1. PEMs isolated from breast
carcinoma cells (0) and breast cancer patients' sera (O) were
adsorbed to the wells of microtest plates and analysed for anti-
body binding by RIA.
each of the MAbs tested is neither lost nor denatured in the
circulating mucin either before or after its release from the
epithelial cell.
Competitive inhibition studies using '251I-labelled NCRC-11
antibody were performed on serum antigen preparations to
ascertain if any of the anti-PEM MAbs recognise the same,
or a topographically related epitope as NCRC-11 MAb.
Table II shows that C568 and NCRC-1 1 MAbs define
separate and distinct epitopes since no inhibition was observ-
ed even at the highest concentration of C568. Of the MAbs
tested, only M8, HMFG-2 and Ca2 inhibited NCRC-11 bin-
ding to any significant extent with this most marked in the
case of the anti-milk fat globule MAb, M8. Thus, these
antibodies either share the same epitope as NCRC-II or their
epitopes are in close enough proximity to cause mutual
inhibition due to steric effects. The latter is most likely in the
case of Ca2 and HMFG-2 where only around 50% inhibition
was observed at the highest concentration of competing anti-
body compared to 86% inhibition in the case of MAb M8
(although these tests do not establish true identity between
epitopes). No inhibition was observed with any of the other
MAbs tested suggesting that they define separate antigenic
determinants to that recognised by NCRC-11. Inefficient
radiolabelling of C568, resulting in a marked loss of
immunoreactivity, has so far prevented a reciprocal study on
the epitope expression of C568 in comparison to other PEM
reactive MAbs.
Neuraminidase treatment ofPEM
On 4% polyacrylamide gels PEM migrates as a series of
bands which correspond to an apparent M, of >400,000
(Figure 5, track 2). Following neuraminidase treatment of
serum PEM, a marked decrease in electrophoretic mobility
was observed, with the molecule barely entering the gel
(Figure 5, track 1). No apparent change in antigenicity was
observed although there was a loss in resolution of the
phenotypic bands. To investigate the role of sialic acid
residues in relation to individual epitope structures, epitope
expression studies on desialylated PEM were undertaken.
1 2
Figure 5 Western blot anlysis of neuraminidase treated PEM.
Purified serum PEM was subjected to neuraminidase digestion as
described in Materials and methods. Digested and undigested
samples were electrophoresed on a 4% polyacrylamide gel and
then transferred on to nitrocellulose. After blocking, the nitro-
cellulose was incubated with NCRC-1 1 antibody followed by
peroxidase conjugated anti-mouse Ig and developed with the
peroxidase substrate 3-amino-9-ethyl carbazole/H202. Track 1
neuraminidase treated PEM; track 2, untreated PEM.
Table 1I Competitive inhibition of 25I-NCRC- Il antibody binding to purified serum PEM
Percentage binding of'25I-labelled NCRC-II in the presence of
Hybridoma tissue culture supernatants'
Dilution" NCRC-JJ C568 HMFG-J HMFG-2 Cal Ca2
100 1 94 87 42 104 56
10-' 19 121 96 83 105 86
10-2 81 113 103 90 108 105
10- 92 112 97 99 98 112
Hybridoma asciticfluids'
Dilution NCRC-lJ C568 M8 M18 115D8 115F5 115G2 NIgM
0o3 0 92 14 84 103 79 95 118
10-4 23 85 31 91 109 72 123 106
10-5 78 93 89 106 130 91 116 106
10-6 109 102 85 100 128 84 106 95
Monoclonal antibodies in atissue culture supernatants and bascitic fluids were tested for their capacity to
inhibit the binding of radiolabelled NCRC-I I antibody at the dilutions shown. CDilutions of competing
antibodies werepredetermined to ensure saturation oftheantigen at leastat the highest concentration used.BREAST TUMOUR ASSOCIATED MUCIN 805
Table III MAb activities to neuraminidase treated serum PEM
Activity (% binding ofcontrol atfollowing concentra-
tions ofneuraminidase (mUml-)a)
MAb 0 10 100
NCRC-ll 100 98 91
C568 100 106 118
C595 100 622 599
Cal 100 35 29
Ca2 100 208 218
Ca3 100 126 135
M8 100 150 149
M18 100 385 380
115D8 100 24 21
115F5 100 98 116
115G2 100 95 106
SM3 - gains activity gains activity
aIncubations were for 2 h at 37°C after which treated and untreated
mucins were tested for retention of MAb binding by RIA.
Table III shows the percentage binding retained of each
antibody relative to untreated material. These results suggest
that sialic acid is not required for maintaining the full
immunoreactivities of MAbs C568 or NCRC-11. Clearly
their epitopes, and those of 115F5 and 115G2, reside within
the underlying sugar residues or on the protein core. Desialy-
lation of PEM led to a marked reduction in the binding
activities of MAbs Cal and 115D8 suggesting that sialic
acids form part of their respective epitopes or are involved in
the conformational presentation of the epitope to its target
antibody. Partial retention of binding suggests that other
sugar residues, or the protein moiety itself, also participate in
the epitope structure. Several MAbs showed an increased
reactivity towards desialylated PEM indicating that they
define cryptic epitopes, masked in the native molecule by the
high degree of sialylation. MAb C595 (Price et al., 1989),
which was raised against urinary PEM, binds at relatively
low levels to serum PEM compared to its high reactivity with
the urinary mucin. However, after desialylation of serum
PEM a 6-fold increase in binding was observed. Similar
results were obtained for MAb M18 which displayed a 3-4-
fold increase in binding. The immunoreactivity of Ca2 was
also enhanced after neuraminidase treatment of the antigen,
and MAb SM3, which is unreactive to native serum PEM,
gained activity following antigen desialylation.
Periodate oxidation ofserum PEM
Mild periodate oxidation of mucins at acidic pH has been
shown to cleave carbohydrate vicinal hydroxyl groups with-
out altering the structure of the polypeptide chain (Bobbit,
1956). In such a manner it is possible to destroy carbo-
hydrate epitopes leaving intact only those epitopes common
to the protein moiety and hence establish the nature of PEM
epitopes. Figure 6 represents the effect oxidative cleavage of
PEM has on the binding of several MAbs relative to their
activity towards untreated material. The binding of MAb
C568 to treated antigen was virtually abolished except at the
lowest concentration of periodate used (1 mM). Likewise,
115D8 reactivity was markedly reduced. Conversely, SM3,
which is unreactive with native serum-derived PEM, gained
binding activity upon periodate treatment of the mucin.
MAbs M8 and HMFG-2 also showed some increase in bind-
ing at the lower concentrations of periodate. The epitopes
identified by these antibodies involve the protein moiety
(Griffiths et al., 1987) which suggests that oxidative cleavage
of glycan residues further exposes their target epitopes. The
binding of NCRC- 1I MAb was unaffected by periodate
treatment except for some decrease in activity at the highest
concentration. However, at high concentrations of periodate
over long incubation times, non-specific oxidation of the
polypeptide chain can occur resulting in partial destruction
of protein epitopes.
These results suggest that the epitope of C568 resides on
the carbohydrate moiety of the molecule whilst that of
NCRC-1 1, like M8 and HMFG-2, involves protein. It should
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Figure 6 Periodate oxidation of PEM isolated from serum. Sam-
ples were incubated (12 h, 4°C) with 100 mM ( S), 10 mM
(El), and 1 mM (E ) sodium periodate in 50mM acetate
buffer (pH 4.5). After reduction with 50 mM sodium borohydride,
treated or untreated ( M ) samples were tested for loss or gain
of antibody binding using several anti-mucin MAbS.
be noted, however, that periodate oxidation cleaves only
those saccharides with vicinal hydroxyls, therefore results
from periodate treatment alone should be interpreted with
caution since it is possible that certain epitopes may reside
upon periodate-resistant sugars (e.g 1+3 linked Gal).
Buoyant density ofPEM
Well-documented evidence reports that mucins exhibit higher
densities than other proteins and glycoproteins, usually in the
range of 1.4-1.5 gml-' (Starkey et al., 1974). Figure 7 shows
fractions recovered after CsCl density gradient centrifugation
of serum PEM which were assayed for PEM activity after
determination of their density. PEM was recovered in a band
corresponding to a density of 1.40-1.45 gml-' with the peak
occuring around 1.43 gml-'. This is in accord with the
expected value for a mucinous protein.
Reductive 13-elimination andprotease digestion ofpurified
serum antigen
Alkaline hydrolysis of PEM under reducing (0.1 N NaOH +
1 M NaBH4) or non-reducing conditions (0.1 N NaOH) sub-
stantially decreased the immunoreactivity of NCRC-l1 anti-
body but had little effect on that of C568 (Table IV).
Proteolytic digestions using the proteases and conditions de-
scribed in Table IV also had little effect on C568 activity
even under exhaustive conditions (18 h) or high protease
concentrations (1OOmUml-'). In contrast, all of the pro-
teases listed, at least at the most extreme of conditions,
decreased NCRC-11 immunoreactivity by varying degrees.
This effect was most pronounced in the case of proteases
sublitisin and papain.
Discussion
Significantly elevated levels of PEM in the circulation of
advanced breast cancer patients provides a convenient source806 C. O'SULLIVAN et al.
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Figure 7 Density gradient centrifugation of PEM. Fractions
were monitored for NCRC- Il antibody binding (0) and buoyant
density (0) as described in Materials and methods.
for the isolation of the molecule. With the exception of
Stacker et al. (1989), to our knowledge, no others have
described the use of serum as a source for PEM purification.
Recent findings have suggested that increased secretion of
PEM into the serum of patients is related to tumour load,
indicating its potential as a marker of malignant disease
(Price et al., 1987). During neoplastic transformation,
tumour-associated alterations in the cell may give rise to
increased synthesis and release of the mucin. In addition, loss
of polarity, typical of transformed cells, may result in the
mode of release being altered from apical to basilateral.
Although these events and others, such as necrosis within the
tumour, may contribute to elevated levels of serum PEM, it
is likely that the disruption of normal tissue architecture due
to malignancy and the associated vascularisation of the
tumour allows the mucin easier access into infiltrating blood
vessels.
In normal tissues PEM is confined to the luminal surface
of glandular epithelial cells or their secretions (Ellis et al.,
1984). That the mucin was detectable in low levels in the
pooled sera of normal individuals (Figure 2), however, raises
the question as to how it enters the circulation from the
apical site of normal resting cells. It is known that PEM
displays a wide tissue distribution and can be isolated from a
variety of epithelial sources, thus it is possible that tissue
damange surrounding sites of mucin expression may account
for low levels of PEM in the serum of certain individuals.
In SDS polyacrylamide gels, PEM migrates as a series of
bands differing slightly in electrophoretic mobility. This is
due to the polymorphism which is seen at both the DNA and
protein level (Swallow et al., 1987; Gendler et al., 1987).
Each band represents one of several phenotypes which are
the products of a number of codominant alleles present at a
single gene locus. In addition to this polymorphism, varia-
tions in glycosylation, in particular differential sialylation,
gives rise to a highly heterogeneous molecular species with
respect to both size and charge.
Desialylation of PEM with neuraminidase resulted in a
marked decrease in electrophoretic mobility (Figure 5). This
occurs due to removal of the intrinsic negative charge which,
in the intact molecule, enhances its migration in an electro-
phoretic field. Thus, the 'apparent' Mr of around 400 kDa of
intact PEM is most likely an under-estimation of its true
molecular weight.
A major characteristic of mucinous glycoproteins is that
they contain a majority of 0-linked glycans (Gottschalk,
1972) and, in the case of PEMs, only a small proportion of
N-linked sugars (Hilkens & Buijs, 1988). Evidence for the
presence of 0-linked glycans is based on the observed P-
elimination mechanism which occurs under mild conditions
of alkali and cleaves carbohydrate residues from the 0-
substituted seryl and threonyl residues on the polypeptide
chain. Under these conditions the protein core is denatured
and this explains the marked decrease in NCRC-11 immuno-
reactivity following P-elimination of serum PEM (Table IV).
The determination of a high buoyant density (1.43 gml-') is
also consistent with a mucinous nature (Figure 7).
The epitope expression of serum PEM was investigated
using several MAbs which identify epitopes on PEMs. The
profile of activity of these antibodies was similar with PEMs
isolated from breast carcinoma cells or from serum (Figure
4), and competition studies have shown that most of their
epitopes are topographically distinct (Table II). The nature of
epitopes common to the serum mucin were further investi-
gated by modification of the antigenic structure by chemical
or enzymatic means. Results obtained following neur-
aminidase digestion of PEM suggest that of the MAbs tested,
115D8 and Cal define epitopes which require sialic acid in
some capacity. Conversely, MAbs C595, SM3 and M18
define cryptic epitopes, fully or partially masked by sialic
acid residues. In the case of M18 this finding was expected
and is consistent with its reported epitope - the I(Ma) blood
group antigen - which is almost totally masked in primary
breast cancers (Foster & Neville, 1984). Antibody SM3,
which was raised against deglycosylated milk mucin and
shows selectivity towards malignant tissue (Burchell et al.,
1987), is unreactive with native serum PEM. Desialylation of
circulating PEM, however, promoted SM3 binding, suggest-
ing that its epitope is not fully exposed in PEM purified from
this source. Similar findings were obtained after periodate
removal of glycan chains and these results are compatible
with the reported epitopes for SM3 and HMFG-2 (Burchell
Table IV Theeffect ofheat, proteolytic digestion and alkaline hydrolysis on theepitopes
for NCRC- II and C568
Activitya
NCRC-11 C568
Conditions 100h 10 1 0.1 100 10 I 0.1
Trypsin I hc 49 81 96 104 - - - -
18 h 21 47 91 86 70 85 106 102
Chymotrypsin I h 92 99 95 95 - - - -
18 h 52 89 90 97 74 83 105 102
Subtilisin 1 h 28 36 52 88 - - - -
18 h 8 24 26 41 100 107 95 75
Pronase 1 h 63 82 90 95
18 h 34 43 74 85 99 89 94 104
Papain I h 10 44 93 97 - - -
18 h 1 0 23 67 103 86 96 94
No treatment 100 100
Heat (IOO°C, 10min) 100 110
0.IN NaOH + IM NaBH4 20 60
0.IMNaOH 6 101
aData areexpressed aspercentage binding(by RIA)relativetountreatedmaterial.bThis
row shows protease concentration (mU ml-'). CAll incubations were at 37°C; alkaline
treatments were for 25 h at 37C.
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et al., 1989). Differential glycosylation of epithelial mucins in
tumours may lead to the exposure of protein epitopes allow-
ing selective binding of MAbs such as SM3. This would infer
that the glycoslyation pattern of circulating PEM is not
necessarily that of the malignant phenotype although this
requires further evaluation.
Oxidative cleavage of glycans by periodate treatment
suggested that the antigenic determinants for C568 is carbo-
hydrate in nature whilst that of NCRC-11 is peptidic and
these findings were further substantiated by protease diges-
tions (Table IV). By way of confirmation of these proposals,
we have recently shown that the NCRC-11 antibody reacts
with synthetic peptide heptamers with sequences based upon
that reported for the core protein of PEM (Gendler et al.,
1987). C568, as expected, does not react with these sequences
(Price et al., 1990). Gendler et al. (1988) proposed that PEMs
each share the same core protein which is coded for by a
single polymorphic gene and exists in a linear conformation
consisting of tandem repeats of 20 amino acids. The number
of repeated sequences, which varies between individuals, is
determined by the observed genetic polymorphism and thus
governs the size of the molecule. An extended rod-like con-
formation would be consistent with the resistance of serum
PEM epitopes to boiling (Table IV) since the molecule is
already in an unfolded form stabilised by extensive glycosyla-
tion.
Along the length of the core protein are attached numer-
ous differentially glycosylated side chains which may develop
tumour-associated variations. Altered patterns of glycosyla-
tion due to incomplete synthesis or neosynthesis of glycans;
aberrant processing of specific glycosyl transferases and/or
tumour glycosidase activity might all result in the develop-
ment of new tumour-associated epitopes. The elucidation and
characterisation of such tumour markers is fundamental to
research into the structure and expression of glycoproteins
during neoplastic progression. Human PEM from sera carries
potentially clinically relevant epitopes and offers a model
system for investigating the biosynthesis and release of a
carcinoma-associated mucin.
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